Characterization of Phase I and Phase II hepatic drug metabolism activities in a panel of human liver preparations

Chemico-Biological Interactions

Volumn 118, Issue 2, 1999, Pages 151-169

  Iyer, Krishna R ^a   Sinz, Michael W ^a  

^a PFIZER INC   (United States)

Author keywords

Cytochrome P450; Cytosol; Human; Liver bank; Microsomes; Phase I enzymes; Phase II enzymes

Indexed keywords

CYTOCHROME P450; DRUG METABOLIZING ENZYME; XENOBIOTIC AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG ACETYLATION; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG SULFATION; ENZYMATIC ASSAY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; LIVER; LIVER MICROSOME; MALE; METHYLATION;

ARYLAMINE N-ACETYLTRANSFERASE; CATALYSIS; CATECHOL O-METHYLTRANSFERASE; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GLUCURONOSYLTRANSFERASE; GLUTATHIONE; HUMANS; LIVER; MALE; MICROSOMES, LIVER; NADP; OXYGENASES; PHARMACEUTICAL PREPARATIONS; TISSUE BANKS;

EID: 0032900852     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(99)00007-1     Document Type: Article

References (53)

1. Low L.K., Castagnoli N. Metabolic changes of drug and related compounds. Doerge R.F. Wilson and Gisvold's Textbook of Organic Medicinal and Pharmaceutical Chemistry. 1982;98-99 J.B. Lippincot, Philadelphia, PA.
2. Paine A.J. Heterogeneity of cytochrome P450 and its toxicological significance. Hum. Exp. Toxicol. 14:1996;1-7.
3. Slaughter R.L., Edwards D.J. Recent advances: The cytochrome P450 enzymes. Ann. Pharmacother. 29:1995;619-624.
4. Stevens J.C., Wrighton S.A. The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol. 22:1992;1-21.
5. Rendic S., Di Carlo F.J. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev. 29:1997;413-580.
6. Zeigler D.M. Flavin-containing monooxygenases: catalytic mechanism and substrate specificities. Drug Metab. Rev. 19:1988;1-32.
7. Armstrong R.N. Structure, catalytic mechanism, and evolution of the glutathione transferases. Chem. Res. Toxicol. 10:1997;2-18.
8. Awasthi Y.C., Sharma R., Singhal S.S. Human glutathione transferases. Int. J. Biochem. 26:1994;295-308.
9. Matsui M., Homma H. Biochemistry and molecular biology of drug-metabolizing sulfotransferase. Int. J. Biochem. 26:1994;1237-1247.
10. Falany C.N. Molecular enzymology of human liver cytosolic sulfotransferases. Trends Pharm. Sci. 12:1991;255-259.
11. Burchell B., Brierly C.H., Rance D. Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation. Life Sci. 57:1995;1819-1831.
12. Mackenzie P.I., Owens I.S., Burchell B., Block K.W., Bairoch A., Belanger A., Fournel-Gigleux S., Green M., Hunt D.W., Iyanagi T., Lancet D., Louisot P., Magdalou J., Chowdhury J.R., Ritter J.K., Schachter H., Tephly T.R., Tipton K.F., Nebert D.W. The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics. 7:1997;255-269.
13. Tephly T.R., Burchell B. UDP-glucuronsyltransferases: a family of detoxifying enzymes. Trends Pharm. Sci. 11:1990;276-279.
14. Kadlubar F.F. Biochemical individuality and its implications for drug and carcinogen metabolism: recent insights from acetyltransferase and cytochrome P4501A2 phenotyping in humans. Drug Metab. Rev. 26:1994;37-46.
15. Weber W.W., Hein D.W. N-Acetylation pharmacogenetics. Pharmacol. Rev. 37:1985;25-79.
16. Weinshilboum R. Methyltransferase pharmacogenetics. Pharmacol. Ther. 43:1989;77-90.
17. Daly A.K., Cholerton S., Gregory W., Idle J.R. Metabolic polymorphisms. Pharmacol. Ther. 57:1993;129-160.
18. Sharer J.E., Shipley L.A., Vandenbranden M.R., Binkley S.N., Wrighton S.A. Comparisons of Phase I and Phase II in vitro hepatic enzyme activities of human, dog, rhesus monkeys, and cynomolgus monkey. Drug Metab. Dispos. 23:1995;1231-1241.
19. Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270:1994;414-423.
20. Gonzalez F.J., Idle J.R. Pharmacogenetic phenotyping and genotyping - present status and future potential. Clin. Pharmacokinet. 26:1994;59-70.
21. Shimada T., Yamazaki H., Mimura M., Wakamiya N., Ueng Y.-F., Guengerich F.P., Inui Y. Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal liver and adult lungs. Drug Metab. Dispos. 24:1996;515-522.
22. Rodrigues A.D. Use of in vitro human metabolism studies in drug development - an industrial perspective. Biochem. Pharmacol. 48:1994;2147-2156.
23. Birkett D.J., Mackenzie P.I., Veronese M.E., Miners J.O. In vitro approaches can predict human drug metabolism. Trends Pharm. Sci. 14:1993;292-294.
24. Lacarelle B., Marre F., Blanc-Gauthier T., Xhou X.J., Placidi M., Catalin J., Rahmani R. Use of human and animal liver microsomes in drug metabolism studies. Eur. J. Drug Metab. Pharmacokinet. 3:1991;458-465.
25. Parkinson A. An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicol. Pathol. 24:1996;45-57.
26. Bardley Jr J.S. Establishment of human tissue banks. Hum. Exp. Toxicol. 13:1994;435-437.
27. Wrighton S.A., Vandenbranden M., Stevens J.C., Shipley L.A., Ring B.J., Rettie A.E., Cashman J.R. In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metab. Rev. 25:1993;453-484.
28. Stevens J.C., Shipley L.A., Cashman J.R., Vandenbranden M., Wrighton S.A. Comparison of human and rhesus monkey in vitro Phase I and Phase II hepatic drug metabolism activities. Drug Metab. Dispos. 21:1993;753-760.
29. Chauret N., Gauthier A., Martin J., Nicoll-Griffith D.A. In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat, and horse. Drug Metab. Dispos. 25:1997;1130-1135.
30. Pearce R.E., McIntyre C.J., Madan A., Sanzgiri U., Draper A.J., Bullock P.L., Cook D.C., Burton L.A., Latham J., Nevins C., Parkinson A. Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity. Arch. Biochem. Biophys. 331:1996;145-169.
31. Yamazaki H., Inoui K., Turvy C.G., Guengerich F.P., Shimada T. Effects of freezing, thawing, and storage of human liver samples on the microsomal contents and activities of cytochrome P450 enzymes. Drug Metab. Dispos. 25:1997;168-174.
32. Human Biologics/Phoenix International product brochure, Scottsdale, AZ, 1997.
33. International Institute for the Advancement of Medicine product brochure, Exton, PA, 1997.
34. Beaune P.H., Kremers P.G., Kaminsky L.S., De Graeve J., Albert A., Guengerich F.P. Comparison of monooxygenase activities and cytochrome P-450 isozyme concentrations in human liver microsomes. Drug Metab. Dispos. 14:1986;437-442.
35. Van der Hoeven T.A., Coon M.J. Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 reductase from rabbit liver microsomes. J. Biol. Chem. 249:1974;6302-6310.
36. Omura T., Sato R. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem. 239:1964;2370-2378.
37. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
38. Tassaneeyakul W., Mohammed Z., Birkett D.J. Caffeine as a probe for human cytochrome P450: validation using cDNA-expression, immunoinhibitin, and microsomal kinetic and inhibitor techniques. Pharmacogenetics. 2:1992;173-183.
39. Fentem J.H., Fry J.R. Metabolism of coumarin by rat, gerbil, and human liver microsomes. Xenobiotica. 22:1992;357-367.
40. Miners J.O, Smith K.J., Robson R.A., McManus M.E., Veronese M.E., Birkett D.J. Tolbutamide hydroxylation by human liver microsomes; kinetic characterization and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochem. Pharmacol. 37:1988;1137-1144.
41. Meier U.T., Kronbach T., Meyer U.A. Assay of mephenytoin in human liver microsomes by high-performance liquid chromatography. Anal. Biochem. 151:1985;286-291.
42. Kronbach T., Mathys D., Gut J., Catin T., Meyer U.A. High-performance liquid chromatographic assays for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-deethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Anal. Biochem. 162:1987;24-32.
43. Tassaneeyakul W., Veronese M.E., Birkett D.J., Gonzalez F.J., Miners J.O. Validation of 4-nitrophenol as an in vitro probe for human liver CYP2E1 using cDNA expression and microsomal kinetic techinques. Biochem. Pharmacol. 46:1993;1975-1981.
44. Sonderfan A.J., Arlotto M.P., Dutton D.R., McMillen S.K., Parkinson A. Regulation of testosterone hydroxylation by rat liver microsomal cytochrome P-450. Arch. Biochem. Biophys. 255:1987;27-41.
45. Sadeque A.J.M., Eddy A.C., Meier G.P., Rettie A.E. Stereoselective sulfoxidation by human flavin containing monooxygenase: evidence for catalytic diversity between hepatic, renal, and fetal forms. Drug Metab. Dispos. 20:1992;832-839.
46. Habig W.H., Pabst M.J., Jakoby W.B. Glutathione S-transferases - the first step in mercapturic acid formation. J. Biol. Chem. 249:1974;7130-7139.
47. Weber W.W. N-acetyltransferase (mammalian liver). Tabor H., Tabor C.W. Methods in Enzymology. 17:1971;805-811 Academic Press, New York.
48. Brevitt S.E., Tan E.W. Synthesis and in vitro evaluation of two progressive series of bifunctional polyhydroxybenzamide catechol O-methyltransferase inhibitors. J. Med. Chem. 40:1997;2035-2039.
49. Pennings E.J.M., Kempen G.M.K.Van Assay of catechol O-methyltransferase by determination of the m- and p-O-methylated products using high-performance liquid chromatography. Anal. Biochem. 98:1979;452-454.
50. Pacifici G.M., Back D.J., L'e Orme M. Sulphation and glucuronidation of paracetamol in human liver: assay conditions. Biochem. Pharmacol. 37:1988;4405-4407.
51. Ekins S., Murray G.I., Burke M.D., Williams J.A., Marchant N.C., Hawksworth G.M. Quantitative differences in Phase I and Phase II metabolism between rat and precision-cut liver slices and isolated hepatocytes. Drug Metab. Dispos. 23:1995;1274-1279.
52. Jacqz-Aigrain E., Bessa E., Medard Y., Mircheva Y., Vilmer E. Thiopurine methyltransferase activity in a French population: h.p.l.c. assay conditions and effects of drugs and inhibitors. Br. J. Clin. Pharamcol. 38:1994;1-8.
53. Weinshilboum R.M., Raymond F.A., Pazmino P.A. Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clin. Chim. Acta. 85:1978;323-333.